Laboratory Of America Holdings Supports Gates Institute's CAR T-Cell Manufacturing with G-Rex Grant
- Gates Institute receives a $300,000 G-Rex Grant to enhance CAR T-cell manufacturing for cell and gene therapy.
- The grant supports a modular platform to optimize resources and improve manufacturing for innovative cancer therapies.
- Gates Institute gains early access to CellReady's G-CAR-T system, boosting operational efficiency in CAR T-cell therapy development.
Transforming Cell and Gene Therapy: Gates Institute Secures G-Rex Grant for CAR T-Cell Manufacturing
The Gates Institute's Translational Sciences Laboratory is set to enhance its capabilities in cell and gene therapy (CGT) with the receipt of a $300,000 G-Rex® Grant from ScaleReady, in collaboration with key industry partners including Wilson Wolf Manufacturing, Bio-Techne Corporation, and CellReady. This grant aims to develop a modular CAR T-cell manufacturing platform that directly addresses the growing demand for efficient and scalable CGT solutions. Dr. Veena Krishnamoorthy, the Director of Translational Sciences at the Gates Institute, highlights the significance of the funding, noting that the platform's design optimizes critical resources such as space, capital, and personnel, while maintaining high standards of cell health and quality.
The modular nature of the platform is particularly relevant in the current landscape of CGT, where personalized therapies are becoming increasingly prevalent. By facilitating structured Design of Experiments (DoE), the G-Rex Grant will enable the Gates Institute to refine its CAR T-cell manufacturing processes. This initiative is expected to assess key variables that influence product attributes, ultimately leading to improved manufacturing options for innovative therapies targeting serious cancers and rare diseases. John Wilson, CEO of Wilson Wolf, commends the Gates Institute for its pivotal role in advancing cell therapies, emphasizing the potential impact of this grant on the development of novel treatment modalities.
Furthermore, the partnership offers the Gates Institute early access to CellReady's G-CAR-TTM, a standardized CAR-T drug manufacturing system known for its high-throughput capabilities. This access not only enhances the institute's operational efficiency but also positions it at the forefront of CAR T-cell therapy development. ScaleReady’s G-Rex Grant Program, which has allocated over $40 million toward CGT development, reinforces the importance of collaboration in this sector, providing recipients with valuable expertise and technology from a consortium of industry leaders.
In addition to the grant's immediate benefits, ScaleReady's initiative underscores a broader commitment to advancing scalable manufacturing practices within the CGT landscape. By supporting innovative projects like that of the Gates Institute, ScaleReady aims to foster a more efficient and effective approach to CGT manufacturing, paving the way for groundbreaking therapies that can meet the needs of patients worldwide. The future of cell and gene therapy is looking brighter as collaborations like these redefine the manufacturing processes essential for bringing life-saving treatments to market.
